-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Market Report Overview IPF is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). ILDs are characterized by damage to the lung parenchyma (the functional part of the lung that includes the alveolar tissue, bronchioles, bronchi, blood vessels, and interstitium) that occurs as a consequence of aberrant inflammation and fibrosis, thickening and scarring of the connective tissue. The development...
-
Company Insights
Roche Holding AG – Enterprise Tech Ecosystem Series
Roche joined forces with GE Healthcare to combine both companies’ capabilities and leverage big data, machine learning, genomics, and imaging technologies to develop decision support tools for clinicians, and help them take data-driven and personalized decisions at each stage of patients’ diseases. In 2013, Roche and California Institute for Quantitative Biosciences (QB3) formed a strategic alliance to create a venture arm, Mission Bay Capital, in order to identify, support, and invest in early stage start-ups focusing on life science, and...
-
Sector Analysis
Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecast to 2025
The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF – Roche's Esbriet and Boehringer Ingelheim's Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014. The top-selling drug in IPF in value terms...
-
Sector Analysis
OpportunityAnalyzer: Myelofibrosis – Opportunity Analysis and Forecasts to 2025
Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is only one approved drug, Incyte/Novartis' Jakafi (ruxolitinib), for the treatment of MF, and other conventional therapies used in MF are off-label. However, none of these drugs are curative, and the only potentially curative intervention is allogeneic stem cell transplant (allo-SCT), which is available to a very small percentage of eligible patients because of the high risk of morbidity and mortality. Therefore, there is...
-
Company Insights
Enterprise Tech Ecosystem Series: Roche Holding AG
Roche joined forces with GE Healthcare to combine both companies’ capabilities and leverage big data, machine learning, genomics, and imaging technologies to develop decision support tools for clinicians, and help them take data-driven and personalized decisions at each stage of patients’ diseases. In 2013, Roche and California Institute for Quantitative Biosciences (QB3) formed a strategic alliance to create a venture arm, Mission Bay Capital, in order to identify, support, and invest in early stage start-ups focusing on life science, and...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for November 2019 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for November 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2019. The report portrays detailed comparative data on the number of deals and their value in the last...